IN THE MIX

● Gennova received ~25 crore funding from Dept of Biotechnology for HGCO19

● Invested ~125 crore for clinical trials and other development of HGCO19

● Was working on MRNA tech for a personalised therapeutic cancer vaccine

● Phase 2/3 trials are on in India

● GOI was eyeing 60 million doses of HGCO19 by December

● Vaccine to be in the market in 2022